Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorChildren's Hospital Medical Center, Cincinnati

About this trial

The investigators hypothesize that single oral high dose supplementation with vitamin A will reduce the incidence of moderate-severe chronic graft-versus-host disease (GVHD) compared with placebo.

Eligibility criteria

Qualifiers

Be 18 years of age or older

Be scheduled for allogeneic stem cell transplant.

Have a vitamin A level < upper limit of normal for age.

Be able to tolerate enteral vitamin dose administration.

Disqualifiers

Ongoing raised intracranial pressure

Liver cirrhosis

Patients will be excluded if they are currently pregnant.

Trial design

Treatments tested in this trial

  • Vitamin A
  • Placebo

Treatment groups

190 Participants
are divided into 2 treatment groups